Multidrug Resistance of Gastric Cancer: The Mechanisms and Chinese Medicine Reversal Agents

Cancer Manag Res. 2020 Dec 2:12:12385-12394. doi: 10.2147/CMAR.S274599. eCollection 2020.

Abstract

Chemotherapy is the main clinical treatment method of gastric cancer. Multidrug resistance (MDR) has become a common phenomenon with the development of tumors, which alleviates the effect of chemotherapy and makes it difficult to break the bottleneck of survival rate of advanced gastric cancer. Therefore, the exploration of MDR reversal agents for gastric cancer is the focus and also the difficulty of current treatment. Currently, the researches on the mechanisms of drug resistance in gastric cancer have been continuously deepened, which reveal different pathways and targets of MDR, laying a solid foundation for studying reversal agents. As a kind of natural medicine, traditional Chinese medicine (TCM) owns the characteristics of low toxicity, high safety and effectiveness. It can inhibit the occurrence, growth and metastasis of tumors, and reverse MDR via multiple pathways and mechanisms, the pathological function of which has become a research hotspot in recent years. TCM reversers are mainly divided into Chinese medicine monomers, Chinese patent medicines, and Chinese herbal compounds. With certain quantity and advantage, TCM reversers for MDR play an important role in the clinical treatment and show great potential in gastric cancer.

Keywords: MDR; TCM; gastric cancer; mechanisms; multidrug resistance; review; traditional Chinese medicine.

Publication types

  • Review

Grants and funding

This research was supported by the National Natural Science Foundation of China (No. 81673918), the Open Projects of the Discipline of Chinese Medicine of Nanjing University of Chinese Medicine supported by the Subject of Academic Priority Discipline of Jiangsu Higher Education Institutions (No. ZYXO3KF020), the Pilot Gastric Cancer Project of Clinical Cooperation of Traditional Chinese and Western Medicine for Major and Difficult Diseases and the National Administration of Traditional Chinese Medicine; and 2019 Project of Building Evidence-Based Practice Capacity for TCM (2019XZZX-ZL003).